From AI-powered drug discovery to quantum computing, this MVP Technology Framework evaluates the tech solutions pharmaceutical companies and contract research organizations (CROs) like Pfizer and IQVIA are using to improve drug discovery.
The drug discovery process is time- and cost-intensive. From discovery to approval, each new drug can take up to 10 years and cost $1B.
Pharma companies are applying emerging technology across the entire pharmaceutical value chain to save time and money.
For example, major players are leveraging AI in drug discovery in multiple ways, including target identification, candidate screening, and laboratory automation. Others are turning to solutions like single-cell sequencing and nature mining to identify new drug candidates.
Pharma players are also exploring simulating biology, organoids, and 3D bioprinting to improve efficiency and efficacy in preclinical testing.
This report evaluates 12 tech markets that pharmaceutical and CRO leaders should monitor, vet, and prioritize.
Want to see more research? Join a demo of the CB Insights platform. If you’re already a customer, log in here.